A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- immune-related (ir)- objective response rate (ORR)
研究概览
简要总结
This phase 2, open-label, single arm study aims to evaluate the efficacy of tremelimumab in combination with the anti-PD-L1 MEDI4736 in patients with unresectable malignant mesothelioma subjects
详细描述
The prognosis of malignant mesothelioma (MM) patients remains dismal and effective treatment represents a high un-met medical need. Investigators have recently reported promising clinical activity of the anti-CTLA-4 mAb tremelimumab in pre-treated MM patients: disease control rate (DCR) was 31%, and survival rate at 1- and 2-years were 48.3% and 36.7%, respectively. These initial findings were corroborated by a second study in which, based on retrospective pharmacokinetic analyses, an intensified schedule of tremelimumab was utilized. Fifty-two % of patients achieved a DCR (median duration 10.9 months). These intriguing clinical results and the emerging efficacy of immunomodulatory mAb targeting the PD-1/PD-L1 axis in different tumor types, prompted us to design the NIBIT-MESO-1 study aimed to investigate the efficacy of tremelimumab combined with the anti-PD-L1 MEDI4736 in MM patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to give written informed consent.
- •Histologic diagnosis of malignant mesothelioma.
- •Subjects who have refused a first line platinum-based chemotherapy, or subjects in progression of disease after a maximum of one line of platinum-based therapy for advanced disease.
- •Disease not amenable to curative surgery.
- •Measurable disease, per modified Response Evaluation Criteria in Solid Tumor [RECIST] for pleural mesothelioma or RECIST version 1.1 for peritoneal mesothelioma).
- •Life expectancy ≥ 12 weeks.
- •ECOG performance status of 0 or 1
- •Normal laboratory tests
- •Negative screening tests for HIV, Hepatitis B, and Hepatitis C.
- •Availability of archival tumor tissue or feasibility to perform a new tumor biopsy at screening phase.
- •Men and women, of and over 18 years old. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 180 days after the last dose of investigational drug.
排除标准
- •Involvement in the planning and/or conduct of the study.
- •Participation in another clinical study with an investigational product during the last 6 weeks.
- •Any previous treatment with a CTLA4, PD-1 or PD-L1 inhibitor, including tremelimumab or MEDI
- •History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study drug and of low potential risk for recurrence. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ.
- •Receipt of the last dose of anti-cancer therapy ≤ 6 weeks prior to the first dose of study drug.
- •Mean QT interval corrected for heart rate (QTc) ≥470 ms using Bazett's Correction.
- •Current or prior use of immunosuppressive medication within 28 days before the first dose of tremelimumab and MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- •Any unresolved toxicity (CTCAE grade >2) from previous anti-cancer therapy.
- •Any prior Grade >3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade
- •Active or prior documented autoimmune or inflammatory disorders
- •History of primary immunodeficiency or allogeneic organ transplant.
- •History of hypersensitivity to tremelimumab or MEDI4736 or any excipient.
- •Uncontrolled intercurrent illness including, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses
- •Known history of previous clinical diagnosis of tuberculosis.
- •History of leptomeningeal carcinomatosis.
- •Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving tremelimumab and MEDI
- •Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids.
- •Subjects with uncontrolled seizures.
研究组 & 干预措施
tremelimumab plus MEDI4736
Tremelimumab in combination with MEDI4736
干预措施: tremelimumab plus MEDI4736 (Drug)
结局指标
主要结局
immune-related (ir)- objective response rate (ORR)
时间窗: 60 weeks
proportion of subjects with complete response \[CR\] or partial Response \[PR\]) according to the ir-modified-RECIST or ir-RECIST 1.1 in pleural or peritoneal subjects, respectively.
次要结局
- Immune-related-progression-free-survival (PFS)(60 weeks)
- Safety (adverse events)(120 weeks)
- Immune-related-ORR based on PD-L1 tumor expression(60 weeks)
- Immune-related-Disease control rate (ir-DCR)(60 weeks)
- Immune-related-progression- free-survival based on PD-L1 tumor expression(60 weeks)
- Overall survival based on PD-L1 tumor expression(120 weeks)
- Disease control rate (DCR)(60 weeks)
- Immune-related-Disease control rate based on PD-L1 tumor expression(60 weeks)
- progression-free-survival (PFS)(60 weeks)
- Overall survival (OS)(120 weeks)